Myriad Genetics Publishes Validation of FirstGene Prenatal Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy MYGN?
Source: Newsfilter
- Validation Results: Myriad Genetics' publication on the FirstGene Multiple Prenatal Screen shows that every test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity, indicating exceptional accuracy and reliability in prenatal screening, which enhances clinicians' confidence in the results.
- Clinical Application Outlook: The test evaluated nearly 500 samples, covering fetal aneuploidy, RhD compatibility, and 19 severe recessive conditions, aiming to streamline prenatal genetic risk assessment by integrating multiple testing modalities, thereby improving screening rates among pregnant women in the U.S. and enhancing clinical practices.
- Technological Innovation: The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to enhance genotype resolution, which not only improves test accuracy but also marks a significant milestone towards broad commercialization of prenatal screening technologies by Myriad.
- CONNECTOR Study Launch: The FirstGene screen is currently utilized in the CONNECTOR study, designed to evaluate test performance in real-world clinical settings, generating evidence to support clinical validity and utility as FirstGene advances towards full commercial launch.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 4.610
Low
4.00
Averages
7.38
High
9.00
Current: 4.610
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMD Partners with Meta for GPU Supply Deal
- AMD and Meta Partnership: AMD has signed a multi-year deal with Meta to supply up to 6 gigawatts of GPUs, which is expected to significantly enhance AMD's market share in AI data centers; while the deal's cost remains unclear, it includes a performance-based warrant potentially involving up to 160 million shares of AMD stock.
- Home Depot Earnings Beat: Home Depot reported fourth-quarter adjusted earnings of $2.72 per share on revenues of $38.20 billion, exceeding analyst expectations of $2.54 per share and $38.12 billion in revenue, indicating strong performance in the home improvement sector.
- Hims & Hers Disappoints: Shares of Hims & Hers Health fell nearly 7% after the company projected first-quarter revenues between $600 million and $625 million, significantly below the $653 million expected by analysts, with adjusted EBITDA also falling short of estimates, highlighting challenges ahead.
- BWX Technologies Strong Results: BWX Technologies reported fourth-quarter earnings of $1.08 per share, surpassing the $0.89 expected by analysts, with revenue of $885.8 million also exceeding the $837.5 million estimate, showcasing its competitive strength in the nuclear components and fuel supply market.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Myriad Genetics Surges 24% After Earnings Beat and 2026 Revenue Target of $860M-$880M
- Earnings Beat: Myriad Genetics reported a non-GAAP EPS of $0.04 for Q4 2025, exceeding expectations by $0.06, with revenue of $209.8 million surpassing forecasts by $2.24 million, indicating strong growth potential in the cancer care sector.
- 2026 Revenue Target: The company has set a revenue target of $860 million to $880 million for 2026, with Q1 2026 revenue expected to range from $200 million to $203 million, reflecting a 2% to 4% growth despite challenges in year-over-year comparisons.
- Market Growth Drivers: CEO Samraat Raha highlighted that Q4 test results reached 382,000, with MyRisk in oncology growing at 14% year-over-year and MyRisk for unaffected individuals at 11%, demonstrating robust demand in high-growth market segments.
- Challenges and Strategies: While facing challenges in recovering prenatal testing volumes, management is actively rebuilding affected accounts to ensure future revenue growth, expressing confidence in sustaining high single-digit growth rates into 2027 and beyond.
See More
Myriad Genetics Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Myriad Genetics reported fourth-quarter revenue of $209.8 million, exceeding the high end of the pre-announced range, indicating strong performance in high-growth market segments that is likely to boost future investments and market confidence.
- Sustained Test Volume Increase: MyRisk tests achieved a year-over-year volume growth of 14% in the affected market and 11% in the unaffected market, demonstrating the company's expanding market share in oncology, which enhances its competitive edge.
- New Product Launch Plans: Management outlined plans to launch multiple new products in 2026, including an expanded MyRisk panel and AI-enhanced Prolaris prostate cancer test, which are expected to enrich the product portfolio and drive future revenue growth.
- 2026 Financial Outlook: The company reaffirmed its revenue guidance for 2026 at $860 million to $880 million, with an adjusted gross margin of 68%-69%, reflecting confidence in future growth while also showcasing a keen awareness of market dynamics.
See More
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
See More
Myriad Genetics Q4 Earnings Exceed Expectations
- Earnings Beat: Myriad Genetics reported a Q4 non-GAAP EPS of $0.04, exceeding expectations by $0.06, indicating robust profitability that boosts investor confidence in the company's financial health.
- Slight Revenue Decline: The Q4 revenue stood at $209.8 million, a 0.4% year-over-year decrease, yet it surpassed expectations by $2.24 million, demonstrating the company's ability to maintain revenue stability in a competitive landscape.
- Volume Growth Drivers: Key drivers of year-over-year test volume growth in Q4 included a 12% increase in Prolaris prostate cancer testing, a 9% rise in hereditary cancer testing, and a 9% growth in GeneSight, reflecting ongoing innovation and demand in precision medicine.
- Stable Gross Margin: The gross margin for Q4 was 70.0%, consistent with Q3, showcasing effective cost management and operational efficiency that support long-term profitability prospects.
See More
AMD Partners with Meta for GPU Supply Deal
- AMD and Meta Partnership: AMD has signed a multi-year deal with Meta to supply up to 6 gigawatts of GPUs, which is expected to significantly enhance AMD's market share in AI data centers; while the deal's cost remains unclear, it includes a performance-based warrant potentially involving up to 160 million shares of AMD stock.
- Home Depot Earnings Beat: Home Depot reported fourth-quarter adjusted earnings of $2.72 per share on revenues of $38.20 billion, exceeding analyst expectations of $2.54 per share and $38.12 billion in revenue, indicating strong performance in the home improvement sector.
- Hims & Hers Disappoints: Shares of Hims & Hers Health fell nearly 7% after the company projected first-quarter revenues between $600 million and $625 million, significantly below the $653 million expected by analysts, with adjusted EBITDA also falling short of estimates, highlighting challenges ahead.
- BWX Technologies Strong Results: BWX Technologies reported fourth-quarter earnings of $1.08 per share, surpassing the $0.89 expected by analysts, with revenue of $885.8 million also exceeding the $837.5 million estimate, showcasing its competitive strength in the nuclear components and fuel supply market.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Myriad Genetics Surges 24% After Earnings Beat and 2026 Revenue Target of $860M-$880M
- Earnings Beat: Myriad Genetics reported a non-GAAP EPS of $0.04 for Q4 2025, exceeding expectations by $0.06, with revenue of $209.8 million surpassing forecasts by $2.24 million, indicating strong growth potential in the cancer care sector.
- 2026 Revenue Target: The company has set a revenue target of $860 million to $880 million for 2026, with Q1 2026 revenue expected to range from $200 million to $203 million, reflecting a 2% to 4% growth despite challenges in year-over-year comparisons.
- Market Growth Drivers: CEO Samraat Raha highlighted that Q4 test results reached 382,000, with MyRisk in oncology growing at 14% year-over-year and MyRisk for unaffected individuals at 11%, demonstrating robust demand in high-growth market segments.
- Challenges and Strategies: While facing challenges in recovering prenatal testing volumes, management is actively rebuilding affected accounts to ensure future revenue growth, expressing confidence in sustaining high single-digit growth rates into 2027 and beyond.
See More
Myriad Genetics Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Myriad Genetics reported fourth-quarter revenue of $209.8 million, exceeding the high end of the pre-announced range, indicating strong performance in high-growth market segments that is likely to boost future investments and market confidence.
- Sustained Test Volume Increase: MyRisk tests achieved a year-over-year volume growth of 14% in the affected market and 11% in the unaffected market, demonstrating the company's expanding market share in oncology, which enhances its competitive edge.
- New Product Launch Plans: Management outlined plans to launch multiple new products in 2026, including an expanded MyRisk panel and AI-enhanced Prolaris prostate cancer test, which are expected to enrich the product portfolio and drive future revenue growth.
- 2026 Financial Outlook: The company reaffirmed its revenue guidance for 2026 at $860 million to $880 million, with an adjusted gross margin of 68%-69%, reflecting confidence in future growth while also showcasing a keen awareness of market dynamics.
See More
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
See More
Myriad Genetics Q4 Earnings Exceed Expectations
- Earnings Beat: Myriad Genetics reported a Q4 non-GAAP EPS of $0.04, exceeding expectations by $0.06, indicating robust profitability that boosts investor confidence in the company's financial health.
- Slight Revenue Decline: The Q4 revenue stood at $209.8 million, a 0.4% year-over-year decrease, yet it surpassed expectations by $2.24 million, demonstrating the company's ability to maintain revenue stability in a competitive landscape.
- Volume Growth Drivers: Key drivers of year-over-year test volume growth in Q4 included a 12% increase in Prolaris prostate cancer testing, a 9% rise in hereditary cancer testing, and a 9% growth in GeneSight, reflecting ongoing innovation and demand in precision medicine.
- Stable Gross Margin: The gross margin for Q4 was 70.0%, consistent with Q3, showcasing effective cost management and operational efficiency that support long-term profitability prospects.
See More
